Familial hypercholesterolemia (FH) is a disease marked by a high incidence of thrombotic episodes and hypersensitivity of the patients' platelets to naturally occurring aggregating agents. Prostaglandin/thromboxane (PG/Tx) formation, adenosine 5-diphosphate (ADP) secretion, and fibrinogen binding to platelets are all believed to be involved in the mechanisms of platelet aggregation. Therefore, we studied the interrelated roles of these processes in the platelets of nine FH patients and 10 controls. In response to ADP, collagen, or thrombin, FH platelets bound about twice as much 12S l-fibrinogen as controls. This ratio did not change after suppression of PG/Tx formation by aspirin. With or without aspirin, FH platelets always aggregated in response to significantly lower concentrations of these agents than did platelets from normal controls. After stimulation with thrombin or collagen, the hyperaggregable platelets from FH patients were shown to bind significantly more fibrinogen than control platelets even when PG/Tx formation was suppressed (aspirin) and secreted ADP was scavenged (apyrase). To determine whether the increased fibrinogen binding observed in FH platelets is due to a qualitative or quantitative abnormality of the platelet receptor, we used a monoclonal antibody (B79.7) that is specific for the receptor. The amount of B79.7 that bound to platelets from control and FH subjects was similar. In addition (as in normal individuals), the antibody inhibited aggregation and fibrinogen binding of FH platelets. (Arteriosclerosis 6
P atients with hypercholesterolemia have a high incidence of atherosclerosis and thrombotic complications. 1 " 7 Familial hypercholesterolemia (FH) is a dominantly inherited disease characterized by extremely high levels of plasma cholesterol and low density lipoproteins (LDL), tendon and cutaneous xanthomata, corneal arcus, and severe atherosclerosis. The homozygous form of this disease involves impaired uptake of cholesterol by arterial walls 89 and clearly points to a role for cholesterol in atherosclerosis. Patients with homozygous familial hypercholesterolemia often exhibit plasma LDL concentrations five times the normal level, associated with severe atherosclerosis and coronary heart disease. Such patients almost invariably die before the age of 30 from the thrombotic complications of atherosclerosis such as myocardial infarction.
Several mechanisms have been suggested by which alterations in plasma lipids may promote atherosclerosis. 7 ' 10~13 Hypercholesterolemia may favor endothelial injury 13 and thus initiate and promote the progress of the atherosclerotic plaque. In addition, high levels of cholesterol can enhance platelet aggregation and prostaglandin (PG) production. In vitro experiments show that the enrichment of normal platelets with cholesterol is associated with increased sensitivity to aggregating agents, increased formation of thromboxane A 2 (TxA 2 ) in response to thrombin, and increased activity of platelet phospholipases. 14 " 18 These findings correlate with the observations that platelets from patients with familial hypercholesterolemia have high levels of free cholesterol 19 associated with in vitro hypersensitivity to aggregating agents; 19 " 22 increased secretion of nucleotides, 21 B-thromboglobulin, and platelet Factor A; 23 and increased formation of malondialdehyde and thromboxane. 22 " 25 Evidence is now accumulating that platelet aggregation involves exposure of receptors for fibrinogen on the platelet surface and binding of fibrinogen to platelets; 26 " 34 that adenosine 5'-diphosphate (ADP) 3a **• 35 as well as PG endoperoxides and thromboxane 33 " 35 secreted by platelets may play a direct role in the exposure of fibrinogen receptors on normal platelets; and that the glycoprotein llb-llla (GPIIb-llla) complex is the receptor for fibrinogen on the platelet surface. 26 ' 28 ' M - 36 " 39 In this paper we examine the roles of ADP secretion and PG endoperoxide/thromboxane formation in the exposure of fibrinogen receptors and aggregation of platelets from nine FH patients. 
Methods

Subjects
Nine FH patients (five females, four males, 7 to 36 years old) and 10 normal, control subjects matched for sex and age were studied. None of the controls had a history of any disease known to alter platelet aggregation. Neither FH patients nor controls had taken any medication for at least 10 days before donating blood. There was no difference between FH subjects (109.9 ± 10.6 mg/dl, mean ± SEM) and controls (112.6 ± 12.5 mg/dl) in total triglyceride levels nor in VLDL triglycerides (79.5 ± 6.1 mg/dl for FH patients and 79.2 ± 1 1 . 6 mg/dl for controls). None of the subjects tested had fasting plasma glucose concentrations above 92 mg/dl. All FH patients were on a hypolipidemic diet with a low content of saturated fatty acids and a polyunsaturated/ saturated fatty acid ratio greater than 1.
Both control and FH subjects had been fasting for 12 to 14 hours at the time of blood collection. Plasma cholesterol and apoprotein profiles ( Table 1) were determined on the blood sample collected for platelet studies. Diagnosis of FH in hypercholesterolemic patients was based upon: 1) a plasma cholesterol level consistently greater than 500 mg/dl with LDL cholesterol always above 450 mg/dl; 2) the appearance of xanthomata in the first decade of life; and 3) the presence of marked hypercholesterolemia in both parents.
Skin fibroblast cultures 8 (kindly performed by Dr. J.L. Goldstein, Dallas, Texas) showed that Patient 3 was LDLreceptor-negative, while Patients 1, 6, and 9 were receptor-defective (less than 15% LDL receptor). The other five patients were not tested. For all the data reported in the results section, no difference was found between Patients 1,3, 6, 9 and the other five FH patients studied. Seven out of nine FH patients exhibited clinical signs of coronary atherosclerosis such as angina pectoris. In six, severe atherosclerotic lesions were confirmed by angiography.
Materials
A 100 mM stock solution of EDTA (Fisher Scientific Company, Fairlawn, New Jersey) was made up in distilled water (pH adjusted to 7.4 with NaOH solution). Bovine serum albumin (Pentex, Fraction V) was purchased from Miles Laboratories Incorporated, Elkhart, Indiana. Apyrase (grade 1), creatine phosphate (CP), creatine kinase (CPK), hirudin (grade IV), ADP, and aspirin (crystalline) were purchased from Sigma Chemical Company, St. Louis, Missouri. Apyrase, hirudin, CP, and ADP were dissolved in distilled water and stored at -2 0° C in small aliquots. Aspirin was dissolved in 0.3 M sodium acetate immediately before each series of experiments. CPK solutions (1 mg/ml in distilled water) were prepared fresh daily.
Arachidonic acid (AA) (more than 99% pure) was provided by Dr. Renato Saggiorato, Menarini, Diagnostic^ Firenze, Italy; it was dissolved in 100 mM sodium carbonate. Ttirombin was purchased from Parke Davis & Company, Detroit, Michigan, was dissolved in distilled water, and was stored in small aliquots at -7 0° C. A stable analogue of prostaglandin endoperoxide/TxAa, U-46619, was kindly provided by Dr. John Pike (the Upjohn Company, Kalama-200, Michigan) and prepared and stored as previously described. 40 Equine tendon collagen was purchased from Hormon Chemie, Munchen, West Germany. Sodium iodide ( 12S I) was from New England Nuclear, Firenze, Italy. Highly specific antibody to TxBj (Seragen Incorporated, Boston, Massachusetts) exhibited less than 0.03% cross reactivity with prostaglandin E 2 , F^, 6-keto-PGF la , or D ? . Silicon oils (methyl-silicone 1.0 DC 200 and Hi phenylsilicone 125 DC 550) were purchased from W.F. Ney Incorporated, Specialty Lubricants, New Bedford, Massachusetts. Mixtures of DC 200 and DC 550 were prepared as described previously. 34 Aspirin tablets (500 mg) were from Bayer Company, West Germany.
Monoclonal Antibodies B79.7 (IgG,) and B59.2 (IgGza) were kindly provided by Dr. Perumal Thiagarajan, Thomas Jefferson University, Philadelphia, Pennsylvania. B79.7 was purified from ascites fluid using a protein A-sepharose column and appeared to be similar to Antibody B59.2 which had been previously shown to be specific for the GPIIb-llla complex. 34 Indeed, like B59.2, Antibody B79.7 inhibited aggregation and fibrinogen binding to platelets in suspension (see results) and bound only negligibly to platelets from three patients with Glanzmann's thrombasthenia. Platelets from these patients lack GPIIbllla.ze. a. as- 39 Moreover like unlabeled B59.2, Antibody B79.7 cross-competes more than 98.7% with labeled Antibody B59.2 for binding on stimulated or unstimulated platelets from controls or FH subjects. For binding studies, the antibodies were labeled with 125 I by the iodine monochloride method 41 and had a specific activity of 470 /tCi/mg protein. For both aggregation and binding studies, mouse immunoglobulins were used as controls. F(ab 1 ) 2 fragments of both antibodies were prepared by peptic digestion of the gammaglobulin and isolation of the fragments on a Protein A-sepharose column. 34 
Preparation of Platelet Suspensions
Blood was collected from FH patients and controls on two occasions, before and 2 hours after ingestion of 500 mg aspirin. For each individual subject and on each occasion, 90 ml of blood were collected from the antecubital vein via a 19-gauge scalp vein needle into a plastic tube containing 10 ml of 3.8% trisodium citrate. Platelet-rich plasma (PRP), obtained by centrifugation (200 g, 15 minutes) at room temperature, was cooled on ice for 30 minutes and EDTA was added to a final concentration of 5.6 mM. After centrifugation at 2000 g for 6 minutes at 4° C in a Beckman, Model J-6B centrifuge (Beckman Analytical, Milano, Italy), the platelets were resuspended in a volume of buffer (0.14 M NaCI, 20 mM Tris, 5 mM glucose, 1 mM EDTA, pH 7.4) equal to that of the discarded plasma; they were centrifuged at 900 g for 6 minutes at room temperature and were resuspended at room temperature at counts in the range of 1 to 5 x 10 8 platelets/ml in a Tyrode's buffer (0.14 M NaCI, 2.7 mM KCI, 1 mM CaCI 2 ,12 mM NaHCO 3 , 0.4 mM NaH 2 PO 4 , pH 7.4) containing 5 mM glucose and 3.5 mg/ml bovine serum albumin. Platelet counts were done by phase contrast microscopy. When trace amounts of 125 l-fibrinogen were added to the PRP, more than 99% of this protein was removed by the washing procedure.
The supernatant of the platelet suspension contained less than 0.5 ^tg/ml fibrinogen as measured by the staphytococcal clumping test (Boehringer Mannheim, Milan, Italy, sensitivity 0.5 iig/ml) 42 and did not aggregate in response to 100 /xM ADP or 1 ^g/ml collagen unless fibrinogen was added. The aggregating response of these platelets in the presence of fibrinogen was 80% to 90% of that seen in autologous PRP and remained unchanged for at least 2 hours. All aggregation and binding studies were conducted within this 2-hour period.
Purification and Labeling of Fibrinogen
Fibrinogen was purified from citrated plasma of normal donors by the method of Martinez et al. 43 The purified fibrinogen contained less than 0.8% immunoassayable fibronectin and von Willebrand factor. Fibrinogen, labeled with 12S I by the iodine monochloride method of McFarlane, 41 had a specific activity of 2.6 to 3.8 x 10 4 cpm//ig protein. Unlabeled and labeled fibrinogen showed the characteristic Aa, B B , and y peaks without any degradation products when electrophoresed on reduced SDS-polyacrilamide gels. 44 Further details of the properties of fibrinogen that was prepared and labelled in this manner have been previously reported. 34 
' 43
Studies on Platelet Aggregation and Thromboxane Formation
Platelet aggregation tests were performed in plastic cuvettes essentially as described elsewhere, 45 except that the ELVI-80 aggregometer, (ELVI Logos, Milan, Italy) was used. The apparatus was adjusted so that the platelet suspension and the buffer produced 10% and 90% light transmittance, respectively.
When thrombin was the stimulus used, hirudin (0.1 U/ml, added 3 minutes after thrombin and immediately before fibrinogen) was used to prevent clotting. ACso was defined as the lowest concentration of an aggregating agent that caused a 50% light transmittance within 3 minutes. TxB 2 levels were measured by radioimmunoassay 34 in aliquots of the supernatant solution removed 3 minutes after the completion of tests for platelet aggregation. The sensitivity was such that as little as 0.5 pmol TxB 2 could be detected.
The effect of aspirin on aggregation and TxB 2 formation was determined on platelet suspensions incubated at 37°C for 30 minutes with 1 to 4 mM aspirin. The effect of apyrase (or CP/CPK) was evaluated by incubating platelet suspensions with 500 to 2000 jiig/ml apyrase (or with 6 mM CP plus 15 U/ml CPK) for 5 minutes before adding aggregating agents. When aspirin and apyrase (or CP/CPK) were used in combination, they were added sequentially.
Studies on Fibrinogen and Antibody Binding to Platelets
Binding of 12s l-fibrinogen or B79.7 to platelets was performed as reported previously 34 with some modifications. Briefly, the time-dependence of binding was studied by incubating 6 ml of unstirred platelet suspension (1-5 x IC^/ml) with either 10 ^iM AA, 1 /xg/ml collagen, 1 AIM U-46619, 10 JJLM ADP, 10 mU/ml thrombin, or with microliter amounts of buffer for 3 minutes at room temperature. Labelled fibrinogen (600 nM) or B79.7 (100 /xg/ml) was then added. At appropriate time intervals, 0.4 ml of the platelet suspension was removed and layered onto 50 /xl of silicone oil in a 0.5 ml micro-Eppendorf tube; free and platelet-bound ligand were separated by centrifugation for 2 minutes at 12,000 g in an Eppendorf centrifuge (Beckman, Milano, Italy) and were counted in a Beckman DP 5500 gammacounter. When thrombin was used, hirudin (0.1 U/ml) was used to prevent clotting and was added 3 minutes after thrombin and immediately before fibrinogen. The effects of increasing concentrations of aggregating agents on the extent of fibrinogen binding to platelets were assessed by incubating unstirred platelet suspensions with ADP (2.5 to 100 /xM), collagen (0.25 to 10 /xg/ml), AA (2.5 to 50 fiM), thrombin (5 to 40 mU/ml), or U-46619 (0.25 to 10 LIM). After 3 minutes, labeled fibrinogen (600 nM) was added, and the extent of binding was determined 5 minutes later. For concentration-response studies, 500 /il aliquots of unstirred platelets were incubated with each aggregating agent (or equal amounts of buffer) for 3 minutes, after which labeled fibrinogen or B79.7 was added at respective final concentrations of 1.5 to 1200 nM or 25 nM to 2 /*M. Fibrinogen binding was measured after 5 minutes and antibody.binding was measured after 1 minute. Specific binding was calculated by subtracting the binding measured in the presence of a 20-fold excess of unlabelled fibrinogen from the total bound fibrinogen. This latter "nonspecific" binding represented 13.8% ± 2.7% SEM of the total bound. Specific fibrinogen binding was not corrected for the amount of this protein bound in the absence of stimulation, which was 4% to 5% of stimulated binding.
For the parallel study of inhibition by antibody B79.7 of aggregation and fibrinogen binding to platelets from FH or control subjects, microliter amounts of B79.7 (from 25 nM to 2 ^M , final concentration) were incubated for 1 minute with 0.25 ml of platelet suspensions which had been stirring at 37° C for 1 minute at 1000 rpm. Collagen (1 /xg/ml) was then added and followed by unlabelled fibrinogen (600 nM, final), and platelet aggregation was measured. In parallel, aliquots of 0.5 ml of unstirred platelet suspensions (1 to 5 x 10^ml) were incubated at room temperature with 1 Mg/ml collagen. After 3 minutes, increasing concentrations (see above) of B79.7 were added, and 1 minute later, 1 2 S I-fibrinogen (600 nM) was added. After 5 minutes, free and platelet-bound fibrinogen were separated on silicons oil and counted.
The in vitro effect of aspirin and/or apyrase (or CP/CPK) on fibrinogen binding to platelets was determined on platelet suspensions processed for platelet aggregation as described above.
Protein Concentration
Protein concentration was calculated from the absorbance at 280 nm by using a 1 % molar extinction coefficient of 15.1 for fibrinogen and 14.3 for antibody. 34
Statistical Analysis and Analysis of the Binding Data
Student's t test for paired or grouped data were used as appropriate for statistical analysis. The binding to platelets of 125 l-fibrinogen was analyzed according to Scatchard as well as Klotz as reported elsewhere. 3448 Informed consent was obtained from all the volunteers in accordance with accepted institutional practice. The studies were carried out according to the principles of the Helsinki declaration.
Results
Platelet Aggregation: Familial Hypercholesterolemla Platelets Compared to Control Platelets
In the absence of added fibrinogen, washed platelet suspensions (1 to 3 x 1Ofyml) from control or FH subjects did not aggregate in response to ADP (100 /iM), collagen (0.2 to 1 Aig/ml), U-46619 (0.5 /xM), or AA (10 to 40 fj.M). They aggregated partially (i.e., about 20% light transmittance) in response to thrombin (10 mU/ml). When fibrinogen (600 nM) was added, full aggregation occurred, and the minimal concentrations of ADP, collagen, and thrombin required to cause 50% light transmittance in the absence of aspirin were lower (p < 0.01) in suspensions from FH patients than in those from control subjects ( Table 2 , compare controls to FH without aspirin for each aggregating agent). The ACso for U-46619 was similar in control and FH platelet suspensions even in the presence of added aspirin. Aspirin suppressed aggregation in response to AA and caused elevation of the ACso for ADP, collagen, or thrombin both in control and FH platelets. It is to be noted that, whether or not aspirin was present in vitro, the AC^, for each of these three agents with FH platelets was less than with control platelets (p < 0.01). Similar results were found using plate- lets obtained from control or FH subjects 2 hours after the ingestion of 500 mg aspirin.
In both control and FH platelet suspensions, a concentration of apyrase (500 nglm\) that suppressed aggregation in response to ADP (10 /xM) inhibited aggregation significantly (p < 0.05), but only partially (27% to 33% of that seen in control, buffered samples) in response to collagen (1 /ig/ml), AA (10 /*M), thrombin (10 mU/ml), or U-46619 (1 ^M). The combination of apyrase (500 /*g/ml) plus aspirin (1 mM) suppressed ADP-and AA-induced aggregation of control or FH platelets, and inhibited aggregation of control platelets exposed to thrombin (10 mU/ml) or collagen (1 fig /m\ ) by about 71% and 77%, respectively, whereas inhibition of aggregation of FH platelets was about 31% and 37%, respectively. This difference in response of FH platelets and control platelets is evident in the example shown in Figure 1 . The eight other FH platelet suspensions gave similar results. Both for control and FH platelets, no further inhibition of aggregation was observed when fourfold higher amounts of aspirin (4 mM) and apy- Values are means ± SEM. AC50 is defined as the lowest concentration of an aggregating agent that causes a 50% light transmittance within 3 minutes. ADP = adenosine 5'-diphosphate; AA = arachidonic acid. *p < 0.01, controls vs FH (both no aspirin). Student's / test for grouped data, t p < 0.01, controls vs FH (both with aspirin). Student's nest for grouped data, i p < 0.01 (no aspirin vs plus aspirin). Student's t test for data. rase (2000 nQlm\) were used or when the higher concentration of aspirin was used in combination with 6 mM CP and 15 U/ml CPK.
TxB 2 Formation In Platelet Suspensions from Normal Subjects or Familial Hypercholesterolemia Patients
At the concentrations of collagen, thrombin, or AA (but not of ADP) studied, there was significantly greater TxBj formation in platelet suspensions from FH patients than in those from controls (Figure 2 ). After aspirin, TxB 2 formation could not be detected (< 0.05 pmol/3 x 10 8 platelets) in response to any of the stimuli used either in platelets from normal subjects or in those from FH patients (data not shown).
Binding of 12S l-Flbrlnogen to Control or Familial Hypercholesterolemia Platelets
Exposure of control or FH platelets to ADP, collagen, thrombin, AA, or U-46619 induced time-dependent binding of fibrinogen that was complete within 3 to 5 minutes (the time period within which platelet aggregation is complete). For all the agents tested, fibrinogen binding was concentration-related and reached a maximum at a final concentration of about 600 nM. Between 5 and 10 minutes after the addition of labeled fibrinogen, more than 85% of this could be displaced by a 20-fold excess of unlabeled fibrinogen. Similar results were obtained if the labeled and unlabeled fibrinogen were added together at the start of the binding reaction. EDTA (10 mM) inhibited 85% to 90% of the fibrinogen binding to stimulated platelets. Maximum fibrinogen binding was induced in both normal and FH platelets by 10 /xM ADP, 1 /Ag/ml collagen, 10 mU/ml thrombin, 10 /J,M AA (Figure 3 ), or by 1 /xM of U-46619 (not shown).
Apparent dissociation constants (Kd) for normal and FH platelets were similar when determined by Scatchard or Klotz analysis (Tables 3 and 4 ) and were comparable to those previously reported. 34 tt At saturating levels of add- ed fibrinogen, however, FH platelets bound 1.5 to two-fold as much ligand as those from normals in response to each aggregating agent tested (Figure 3) . Aspirin, either ingested 2 hours before or added in vitro (1 mM) 30 minutes before testing, did not affect binding in control or FH platelets exposed to U-46619, suppressed binding in response to AA, and significantly decreased binding in response to ADP, collagen or thrombin ( Table 5 ). Regardless of aspirin, however, the amount of fibrinogen bound to FH platelets was always significantly greater than the amount of fibrinogen bound to control platelets in response to these three agents. Apyrase (500 ^g/ml) almost completely (more than 98%) inhibited binding in response to ADP (10 //.M) and reduced by 33% to 39% (p < 0.05 for all the agents tested) binding to control or FH platelets exposed to AA (10 jtM), collagen (1 /ig/ml), or thrombin (10 mU/ml). Similar results were obtained when 6 mM CP plus 15 U/ml CPK were used instead of apyrase. The combination of aspirin (1 mM) and apyrase (500 /xg/ml) inhibited binding of fibrinogen to control platelets in response to thrombin or collagen by about 94% and FH platelets by about 85% (Figure 4 ). For both control and FH platelets, no further inhibition of binding was observed when four-fold higher concentrations of aspirin (4 mM) and apyrase (2000 tg/ml) were used, or when aspirin was used in combination with 6 mM CP and 15 U/ml CPK. Identical results were obtained when apyrase (500 to 2000 /xg/ml) was added to platelets obtained from control or FH subjects 2 hours after ingestion of 500 mg aspirin. Apyrase (500 jig/ml) alone (not shown) or in combination with 1 mM aspirin ( Figure 4 ) decreased fibrinogen binding in response to U-46619 by about 75% in both control and FH platelets. Similar results were found when 6 mM CP and 15 U/ml CPK were used in combination with 1 to 4 mM aspirin. 
Binding of Antibody B79.7 to Platelets
Binding of 125 I Antibody B79.7 (or of labeled B59.2) to unstimulated platelets was complete in 1 minute. The amount of specific B79.7 binding at saturation was similar in control and FH platelets (3.61 ±2.13 pmol/10 8 platelets in normal vs 3.89 ± 1.97 in FH subjects, p > 0.01). Pretreatment of platelets with aspirin (1 mM) alone or in combination with apyrase (500 to 2000 /ug/ml) did not affect the amount of binding observed. The amount of Antibody B79.7 bound was not increased by pretreating platelet suspensions from control or FH subjects with ADP (10 /iM), collagen (1 /xg/ml), thrombin (10 mU/ml), or U-46619 (1
Inhibition of Platelet Aggregation and Fibrinogen Binding by Antibody B79.7
It has been previously shown that Antibody B59.2 Inhibits aggregation, secretion, and binding of fibrinogen to normal platelets stimulated by ADP, collagen, or AA. 34 Similarly, Antibody B79.7 (but not equimolar concentrations of mouse immunoglobulins) inhibited aggregation and fibrinogen binding to FH or control platelets in a concentrationdependent fashion (Figure 5 ). At a 0.2 /xM concentration of B79.7, aggregation in response to collagen was suppressed in both types of platelets, and fibrinogen binding to FH platelets stimulated with ADP, collagen, thrombin, AA, or U-46619 was similar to that seen in suspensions from control platelets ( Table 6 ). Similar results were found when a 0.2 jtM concentration of F(ab 1 ) 2 fragments of B79.7 were used (data not shown). When 10 times as much antibody was used (2 nM), the binding of fibrinogen to platelets from normal and FH subjects was inhibited by more than 95% (data for platelets from FH patients shown in Figure 5 ).
Discussion
Platelets from FH patients are more sensitive to aggregating agents (references 20-22 and this study) and form more prostaglandins and thromboxane (references 22, 25 and this study) than normal platelets. We have now found abnormally high fibrinogen binding to FH platelets in response to ADP, collagen, AA, or thrombin. Regardless of the method of analysis employed, the dissociation constants for fibrinogen were similar for all the agents and comparable in platelets from normal subjects and FH patients, while the number of molecules bound to FH platelets was significantly higher than normal. The order of activity of the various aggregating agents was similar in control and FH platelets. As with normal subjects, ADP was least effective, collagen and AA had intermediate effects, and thrombin was most potent. Since all these agents induce ADP secretion as well as PG/Tx synthesis, 15 ' * 7~so we used aspirin (a cyclooxygenase inhibitor) and apyrase (an ADP scavenger) to examine the possible role of these processes in the abnormally high fibrinogen binding to FH platelets. At a concentration that completely inhibited fibrinogen binding in response to 10 /xM ADP both in platelets from normal subjects and FH patients, apyrase (or CP/CPK) decreased binding in response to AA, collagen, or thrombin by 30% to 40%. Aspirin abolished AAinduced binding and reduced binding to control and FH platelets exposed to ADP, collagen, or thrombin by 50% or more. The combination of aspirin and apyrase suppressed binding of fibrinogen to control or FH platelets exposed to ADP or AA and produced significant (95% and 85%, respectively) but not complete inhibition of binding to normal and FH platelets exposed to collagen or thrombin.
The very low concentrations of thrombin that we used in our study explain the marked inhibition of platelet aggregation and fibrinogen binding in response to the combination of aspirin plus apyrase, since it is known that aggregation by low concentrations of thrombin depends on prostaglandin synthesis and nucleotide secretion. 47 " 50 The AC50 and the amount of fibrinogen binding and aggregation in response to U-46619 were similar and were reduced in similar fashion by aspirin and/or apyrase in both types of platelets. This suggests that in FH platelets, neither qualitative nor quantitative abnormalities of the platelet receptor for fibrinogen are involved in the increased aggregation and binding observed in response to ADP, collagen, AA, or thrombin. This is also suggested by studies in which monoclonal antibodies to the platelet receptor for fibrinogen are used ( Table 6) .
It is currently believed that the GPIIb-llla complex is the receptor for fibrinogen on the platelet surface and that normal platelets have about 40,000 to 50,000 of these receptors. 28 '"• 29 " 39 Our antibodies only detected 20,000 to 30,000 sites on normal as well as FH platelets. A similar finding has also been reported for another monoclonal antibody to the platelet receptor for fibrinogen 51 It is possible that divalent antibodies could have bound to different, but adjacent, GPIIb-llla resulting in an underestimation of the number of these complexes. On the other hand, as suggested by Melero and Gonzalez-Rodriguez, 51 it is conceivable that the epitope of the GPIIb-llla complex that reacts with our antibodies, as well as with their antibody, is not readily available on the platelet surface. This would be consistent with the observation that treatment with proteolytic enzymes almost doubles the number of binding sites for B59.2 on normal platelets (S. Niewiarowski, personal communication).
With 40,000 to 50,000 GPIIb-llla complexes on platelets, one would expect to find 40,000 to 50,000 molecules of fibrinogen bound per platelet. This number is an average value and many examples of wide variations are present in the literature. For example, Coller et al. 37 found that their antibody to the GPIIb-llla binds to as few as 12,000 and to as many as 83,000 sites on platelets from normal subjects. Plow and Marguerie 30 reported that at maximal exposure of binding sites for fibrinogen, some normal subjects may have as many as 76,000 sites capable of binding this protein. Niewiarowski et al. 31 reported an average of 80,000 sites for fibrinogen on platelets from normal individuals, and Kornecki et al. 38 found 88,000 to 400,000 sites for fibrinogen after treatment of platelets with ADP or chymotrypsin. Since these authors reported affinity constants for fibrinogen comparable to those found in studies in which 40,000 to 50,000 sites were observed, one has to assume that either more than 40,000 to 50,000 GPIIb-llla sites are present on normal platelets or that additional binding sites (with an affinity for fibrinogen similar to that of the GPIIbllla complex) come into play. While there is no definite answer to this question, it is worth mentioning that thrombospondin secreted by platelets after exposure to thrombin or collagen can bind to free fibrinogen, as well as to fibrinogen already bound to GPIIb-llla, and that this interaction may play a major role in enhancing platelet aggregation. 52 It has previously been shown that the secretion of other granular components is increased in platelets from FH patients. 23 There may be increased secretion of thrombospondin in hypercholesterolemia to favor increased binding of fibrinogen and to reinforce the strength of a hemostatic platelet plug or a thrombus. This might also explain the abnormally high sensitivity of FH platelets to collagen and thrombin.
We did not find a direct correlation between inhibition of fibrinogen binding and inhibition of platelet aggregation by the combination of aspirin plus apyrase. A possible explanation for this may be that fibrinogen is secreted from platelets in response to thrombin or collagen in amounts that may favor aggregation but are not sufficient to detectably compete with exogenous labeled fibrinogen for binding to platelets.
We found that the smallest amount of ADP that induces 50% aggregation in the presence of aspirin (which inhibits secretion and secretion-dependent aggregation) is significantly lower in platelets from FH patients. This suggests that platelets from these patients also have enhanced primary aggregation, since only primary aggregation is measured in the presence of aspirin. 53 In spite of uncertainties concerning the mechanisms involved in the abnormally high binding of fibrinogen to FH platelets, the observation that a monoclonal antibody to the platelet receptor for fibrinogen inhibits the aggregation of platelets from FH patients suggests that therapy with this kind of antibody or drugs that have similar effects on platelets might reduce the number of thrombotic episodes in FH patients.
